A public biotech company wanted to understand the orphan drug designations (ODDs) opportunities that existed in the acute kidney injury (AKI) space.
MSC was engaged to provide the management and Board of Directors with a foundation of strategic considerations about orphan designations in the major regions and to scout for the company’s orphan opportunities in the AKI field. Rare diseases as related to kidney diseases and AKI were mapped alongside with competing players holding ODDs in the space. A selection of orphan drug strategies was presented for the selected identified rare diseases together with high-level reported prevalence data in the key region of interest. The outcome was used to prioritize between the identified orphan opportunities and to create a shortlist of those with the highest fit with the company’s business.